Recently Approved

June 2007
Pharmaceutical Representative;Jun2007, Vol. 37 Issue 6, p16
The article presents newly approved health products. The U.S. Food and Drug Administration has approved GlaxoSmithKline's antibiotic Altabax 1% for the topical treatment of impetigo. SkyePharma Inc. and Enzon Pharmaceuticals Inc. have received full approval of DepoCyt, which was previously granted for the treatment of patients with lymphomatous meningitis. Enjuvia from Duramed Pharmaceuticals Inc. has been approved for use in the treatment of moderate-to-severe vaginal dryness and pain.


Related Articles

  • FDA Refuses to Approve SkyePharma Asthma Drug.  // BioWorld International;1/27/2010, Vol. 15 Issue 4, p4 

    The article reports on the refusal of the U.S. Food and Drug Administration (FDA) to approve the Flutiform drug of SkyePharma PLC for the treatment of asthma.

  • New approvals.  // Pharmacy Today;Jan2009, Vol. 15 Issue 1, p16 

    The article reports on the approval given by the U.S. Food and Drug Association (FDA) to two therapeutic drugs. FDA has approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults from Johnson & Johnson. It also approved Duramed Inc.'s Synethic...

  • COMPANY SPOTLIGHT -- Enzon Pharmaceuticals.  // PharmaWatch: Cancer;Jun2007, Vol. 6 Issue 6, p16 

    The article profiles the company Enzon Pharmaceuticals Inc., a U.S.-based biopharmaceutical company that is focused on the development, manufacture, and commercialization of pharmaceutical products. The company's success in terms of drug approvals, including the approval on its lymphomatous...

  • Inex and Enzon reveal FDA acceptance of Onco TCS new drug application.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p14 

    Reports on the revelation made by Inex Pharmaceuticals Corp. and Enzon Pharmaceuticals that the new drug application for Onco TCS vincrisine sulfate liposomes injection was accepted by the U.S. Food and Drug Administration and was granted a standard review designation. Target date for the...

  • WASHINGTON INSIDER: Update.  // Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p15 

    The article offers news briefs related to the U.S. Food and Drug Administration (FDA). The FDA comments that a flash card for Enzon Inc.'s Abelcet can contribute to the drug's unsubstantiated superiority claims. Public Citizen filed a citizen position with the FDA and asked that its experts be...

  • SkyePharma: Flutiform held back.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p24 

    The article reports on the decision of SkyePharma PLC to delay its application of Flutiform for approval for the treatment of asthma in Europe. The decision was caused by a patient mix-up at a high-dose registration study due to a randomization issue. It is believed that the delay would raise a...

  • FDA Refuses to Approve SkyePharma Asthma Drug.  // BioWorld Today;1/22/2010, Vol. 21 Issue 14, p2 

    This article reports on the U.S. Food and Drug Administration's refusal of a new drug application submitted by SkyePharma PLC for its asthma drug.

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/19/2008, Vol. 19 Issue 54, p7 

    This section offers news briefs on the biopharmaceutical industry. The preclinical data for PEG-SN38 from Enzon Pharmaceuticals Inc. is published in the March 15, 2008, issue of the "Clinical Cancer Research." The U.S. Food and Drug Administration (FDA) has given milatuzumab from Immunomedics...

  • Applications Update.  // PharmaWatch: Biotechnology;Feb2007, Vol. 6 Issue 2, p9 

    The article offers news briefs related to the biotechnological industries. Epix Pharmaceuticals Inc. has to appeal against the decision of the Food and Drug Administration (FDA) involving the previous denial of its blood-pool imaging agent. Gilead Sciences Inc. asked the FDA for marketing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics